Effectiveness and Safety of Vagus Nerve Stimulation for Severe Treatment-Resistant Major Depression in Clinical Practice After FDA Approval: Outcomes at 1 Year
The DOI matches its Crossref record.
Abstract
Article AbstractObjective: To describe the outcomes of a consecutive series of depressed patients treated with vagus nerve stimulation (VNS) following US Food and Drug Administration (FDA) approval of this intervention. Method: We implanted a VNS device in 15 consecutive outpatients with treatment-resistant major depressive episodes, including 10 with major depressive disorder and 5 with bipolar disorder (DSM-IV criteria), between November 2005 and August 2006. Existing antidepressant treatment remained fixed as far as clinically possible. The primary outcome was change from baseline in the Beck Depression Inventory (BDI) score. Outcomes were assessed at 6 and 12 months postimplant and compared to those of the VNS pivotal efficacy trial that led to FDA approval of VNS. Results: The BDI score decreased significantly compared to baseline at 6 months (P < .05) and 12 months (P < .01), from a mean of 37.8 (SD = 7.8) before VNS activation to a mean of 24.6 (SD = 11.4) at 12 months. By 1 year, 28.6% (n = 4) of the sample responded to VNS and 7.1% (n = 1) remitted according to the BDI. Secondary outcomes on the Hamilton Depression Rating Scale 24-Item showed similar improvement at 1 year, with a 43% response rate (n = 6) and 14.3% remission rate (n = 2). No obvious predictors of response were detected. Side effects of VNS included hoarseness (73%), dyspnea (47%), nausea (40%), pain (33%), and anxiety (20%); no patient terminated treatment due to intolerable side effects. Conclusions: We found that a substantial minority of patients with extremely difficult-to-treat depressive disorders benefited from VNS in an ambulatory clinical practice, with outcomes comparable to those observed in previous VNS efficacy studies and with a similar side effect profile. J Clin Psychiatry Submitted: December 7, 2009; accepted April 7, 2010. Online ahead of print: January 11, 2011 (doi:10.4088/JCP.09m05888blu). Corresponding author: Pilar Cristancho, MD, Mood and Anxiety Disorders Treatment and Research Program, University of Pennsylvania School of Medicine, 3535 Market St, Ste 4002, Philadelphia, PA 19104 (pilar.cristancho@uphs.upenn.edu).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Heart rate variability biofeedback: how and why does it work?
Lehrer, P. M., & Gevirtz, R. (2014) · Frontiers in Psychology · doi:10.3389/fpsyg.2014.00756 · Cited by 883
“One possible clue came from the recent research using vagal nerve stimulation for severe depression (and seizure disorders; Sackeim et al., 2001a,b; Nahas et al., 2005; Daban et al., 2008; George et al., 2008; Cristancho et al., 2011).”
BackgroundMicrobiota-Gut-Brain Axis: New Therapeutic Opportunities
Long-Smith, C., O'Riordan, K. J., Clarke, G., Stanton, C., Dinan, T. G., & Cryan, J. F. (2020) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010919-023628 · Cited by 419
Farmer, A. D., Strzelczyk, A., Finisguerra, A., Gourine, A. V., Gharabaghi, A., Hasan, A., Burger, A. M., Jaramillo, A. M., Mertens, A., Majid, A., et al. (2021) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2020.568051 · Cited by 355
Harshaw, C. (2015) · Psychological Bulletin · doi:10.1037/a0038101 · Cited by 302
“That is, case studies (e.g., Borckardt et al., 2006; Critchley et al., 2007), studies of VNS efficacy without controls (e.g., Christmas et al., 2013; Cristancho et al., 2011), studies comparing only various levels of VNS intensity (e.g., Aaronson et al., 2013), and studies focused solely on…”
BackgroundTreatment-resistant depression and suicidality
Bergfeld, I. O., Mantione, M., Figee, M., Schuurman, P. R., Lok, A., & Denys, D. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.04.016 · Cited by 256
Perez-Burgos, A., Wang, B., Mao, Y.-K., Mistry, B., Neufeld, K.-A. M., Bienenstock, J., & Kunze, W. (2013) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00128.2012 · Cited by 235
Frangos, E., & Komisaruk, B. R. (2017) · Brain Stimulation · doi:10.1016/j.brs.2016.10.008 · Cited by 205
“Electrical stimulation applied directly to the main trunk of the vagus in the neck via surgically implanted electrodes has been used therapeutically to treat refractory epilepsy and depression, but requires costly invasive surgery andmay generate side effects including hoarseness, dyspnea, nausea, pain, and anxiety [1…”
MethodVagus nerve stimulation in psychiatry: a systematic review of the available evidence
Cimpianu, C.-L., Strube, W., Falkai, P., Palm, U., & Hasan, A. (2017) · Journal of Neural Transmission · doi:10.1007/s00702-016-1642-2 · Cited by 138
Posttraumatic stress disorder: does the gut microbiome hold the key?
Leclercq, S., Forsythe, P., & Bienenstock, J. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716635535 · Cited by 121
The antidepressant mechanism of action of vagus nerve stimulation: Evidence from preclinical studies
Grimonprez, A., Raedt, R., Baeken, C., Boon, P., & Vonck, K. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.06.019 · Cited by 81
Rizvi, S. J., Donovan, M., Giacobbe, P., Placenza, F., Rotzinger, S., & Kennedy, S. H. (2011) · International Review of Psychiatry · doi:10.3109/09540261.2011.630993 · Cited by 42
“Other common symptoms reported are nausea, dizziness, shortness of breath, pain, and anxiety (Bajbouj et al., 2010; Cristancho et al., 2011).”
BackgroundThe allure of transcutaneous vagus nerve stimulation as a novel therapeutic modality
Carreno, F. R., & Frazer, A. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.11.016 · Cited by 34
Metadata
- Authors
- Cristancho, P., Cristancho, M. A., Baltuch, G. H., Thase, M. E., & O’Reardon, J. P.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2011-01-11
- Volume
- 72
- Issue
- 10
- Pages
- 1376-1382
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2123072961
- Cited by
- 142
- References
- 0
- FWCI
- 4.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.